Hormone Receptor Status Predicts the Clinical Outcome of Human Epidermal Growth Factor 2-positive Metastatic Breast Cancer Patients Receiving Trastuzumab Therapy: a Multicenter Retrospective Study

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2015 Dec 10

PMID 26648738

Citations 6

Authors

Yunchao Wang

Tao Sun

Donggui Wan

Lijun Sheng

Wei Li

Huayun Zhu

Yanping Li

Janice Lu

Affiliations

Soon will be listed here.

Abstract

Objectives: Trastuzumab, a humanized monoclonal antibody that binds human epidermal growth factor receptor 2 (HER2), dramatically improves the clinical outcomes of HER2-positive breast cancer. Emerging evidence implied that the clinical behavior and sensitivity to targeted agents in HER2-positive breast cancer differed by hormone receptor (HR) status. The objective of this study was to determine the effect of the HR status on survival benefit of HER2-positive metastatic breast cancer when treated with anti-HER2-targeted therapy in People's Republic of China.

Methods: Metastatic breast cancer patients with HER2-positive diseases across six cancer centers in People's Republic of China were retrospectively analyzed in our study. Patients were classified into four groups according to HR/HER2 status and trastuzumab treatment: HER2+/HR+ patients with first-line trastuzumab treatment, HER2+/HR+ patients with no trastuzumab treatment, HER2+/HR- patients with first-line trastuzumab treatment, and HER2+/HR- patients with no trastuzumab treatment. Kaplan-Meier analysis, log-rank test, and multivariate analysis were performed during analysis.

Results: A total of 295 patients were included in the final analysis. The median overall survival was 30 months (95% confidence interval: 27.521-32.479). Among patients with HER2+/HR- disease, significant survival benefit was observed when treated with trastuzumab (30 vs 21 months, P=0.000). However, in patients with HER2+/HR+ disease, trastuzumab administration had a survival improvement trend but no significant statistical differences (36 vs 30 months, P=0.258). In the multivariate analysis, HR status was an independent predictor of overall survival and trastuzumab treatment had significantly decreased risk of death in HER2+/HR- patients (hazard ratio =0.330).

Conclusion: HR status is an independent predictor of overall survival in HER2-positive metastatic breast cancer patients and patients with HER2+/HR- subtype might be associated with more survival benefits when treated with trastuzumab-based regimens.

Citing Articles

Investigating the Correlation Between Long-Term Response in Patients with Metastatic HER2+ Breast Cancer and the Activity of Regulatory T Cells: A Retrospective Study.

Degirmenci M, Diniz G, Kahraman D, Sahbazlar M, Koral L, Varol U Breast Cancer (Dove Med Press). 2024; 16:645-655.

PMID: 39355199 PMC: 11444060. DOI: 10.2147/BCTT.S470570.

Efficacy of everolimus-based therapy in advanced triple-positive breast cancer: Experience from three cancer centers in China.

Tan Y, Jiang H, Ma F, Wang J, Zhang P, Li Q Thorac Cancer. 2023; 14(34):3397-3405.

PMID: 37936567 PMC: 10693944. DOI: 10.1111/1759-7714.15133.

Outcomes for the first four lines of therapy in patients with HER2-positive advanced breast cancer: results from the SONABRE registry.

Ibragimova K, Geurts S, Meegdes M, Erdkamp F, Heijns J, Tol J Breast Cancer Res Treat. 2023; 198(2):239-251.

PMID: 36635428 PMC: 10020272. DOI: 10.1007/s10549-022-06832-9.

Epidemiological characteristics, clinical outcomes and management patterns of metastatic breast cancer patients in routine clinical care settings of Greece: Results from the EMERGE multicenter retrospective chart review study.

Kotsakis A, Ardavanis A, Koumakis G, Samantas E, Psyrri A, Papadimitriou C BMC Cancer. 2019; 19(1):88.

PMID: 30658600 PMC: 6339387. DOI: 10.1186/s12885-019-5301-5.

Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic....

Johnston S, Hegg R, Im S, Park I, Burdaeva O, Kurteva G J Clin Oncol. 2017; 36(8):741-748.

PMID: 29244528 PMC: 7444639. DOI: 10.1200/JCO.2017.74.7824.

References

Hess K, Esteva F . Effect of HER2 status on distant recurrence in early stage breast cancer. Breast Cancer Res Treat. 2012; 137(2):449-55. PMC: 3544467. DOI: 10.1007/s10549-012-2366-0. View

Sihto H, Lundin J, Lundin M, Lehtimaki T, Ristimaki A, Holli K . Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study. Breast Cancer Res. 2011; 13(5):R87. PMC: 3262199. DOI: 10.1186/bcr2944. View

Park Y, Lee S, Cho E, La Choi Y, Lee J, Nam S . Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status. Cancer Chemother Pharmacol. 2009; 66(3):507-16. DOI: 10.1007/s00280-009-1190-7. View

Hoefnagel L, van de Vijver M, van Slooten H, Wesseling P, Wesseling J, Westenend P . Receptor conversion in distant breast cancer metastases. Breast Cancer Res. 2010; 12(5):R75. PMC: 3096964. DOI: 10.1186/bcr2645. View

Collins D, Cocchiglia S, Tibbitts P, Solon G, Bane F, McBryan J . Growth factor receptor/steroid receptor cross talk in trastuzumab-treated breast cancer. Oncogene. 2014; 34(4):525-30. DOI: 10.1038/onc.2013.586. View

Untch M, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer J . Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol. 2012; 13(2):135-44. DOI: 10.1016/S1470-2045(11)70397-7. View

Piccart-Gebhart M, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I . Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353(16):1659-72. DOI: 10.1056/NEJMoa052306. View

Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M . Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011; 365(14):1273-83. PMC: 3268553. DOI: 10.1056/NEJMoa0910383. View

Wang Y, Morrison G, Gillihan R, Guo J, Ward R, Fu X . Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation. Breast Cancer Res. 2011; 13(6):R121. PMC: 3326563. DOI: 10.1186/bcr3067. View

10.

Incorvati J, Shah S, Mu Y, Lu J . Targeted therapy for HER2 positive breast cancer. J Hematol Oncol. 2013; 6:38. PMC: 3703272. DOI: 10.1186/1756-8722-6-38. View

11.

Tanioka M, Sasaki M, Shimomura A, Fujishima M, Doi M, Matsuura K . Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status. Breast. 2014; 23(4):466-72. DOI: 10.1016/j.breast.2014.03.008. View

12.

Gianni L, Pienkowski T, Im Y, Roman L, Tseng L, Liu M . Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2011; 13(1):25-32. DOI: 10.1016/S1470-2045(11)70336-9. View

13.

Goldhirsch A, Ingle J, Gelber R, Coates A, Thurlimann B, Senn H . Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009; 20(8):1319-29. PMC: 2720818. DOI: 10.1093/annonc/mdp322. View

14.

Guarneri V, Broglio K, Kau S, Cristofanilli M, Buzdar A, Valero V . Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol. 2006; 24(7):1037-44. DOI: 10.1200/JCO.2005.02.6914. View

15.

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

16.

Wolff A, Hammond M, Schwartz J, Hagerty K, Allred D, Cote R . American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2006; 25(1):118-45. DOI: 10.1200/JCO.2006.09.2775. View

17.

Qin T, Yuan Z, Peng R, Bai B, Shi Y, Teng X . HER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negative breast cancer patients. Onco Targets Ther. 2013; 6:341-7. PMC: 3626365. DOI: 10.2147/OTT.S40851. View

18.

Montemurro F, Rossi V, Cossu Rocca M, Martinello R, Verri E, Redana S . Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients. Cancer. 2011; 118(1):17-26. DOI: 10.1002/cncr.26162. View

19.

Romond E, Perez E, Bryant J, Suman V, Geyer Jr C, Davidson N . Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005; 353(16):1673-84. DOI: 10.1056/NEJMoa052122. View

20.

Lal P, Tan L, Chen B . Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. Am J Clin Pathol. 2005; 123(4):541-6. DOI: 10.1309/YMJ3-A83T-B39M-RUT9. View